ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer.

Aditya Bardia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.